Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/nicotine/section/safety.full@1

sectionreferenced by edges — no row of its own

derived from · upstream

feeds · downstream

none recorded

Closure of psx:substance/nicotine/section/safety.full@1: 107 upstream, 81 downstream.

psx:substance/nicotine/section/safety.full@1
├─ informed_by  claim/38bf3755-2e1a-4df5-ae54-af1661e98ae9  Claim in safety — inconclusive  working
├─ informed_by  claim/0fb5ebc0-2d2d-4929-972f-4eb7fdee8df6  Claim in safety — inconclusive  working
├─ informed_by  claim/92cf20e6-8270-450d-a052-9a9fa809805e  Claim in safety — inconclusive  working
├─ informed_by  claim/9a8fbb90-39af-4368-a380-9310459ffd7b  Claim in safety — inconclusive  working
├─ informed_by  claim/2f74dbb5-e713-4823-91e3-aa370c41d0ce  Claim in safety — inconclusive  working
├─ informed_by  claim/f9f9ab1d-3e6b-47e9-aa1c-b3539596155f  Claim in safety — inconclusive  working
├─ informed_by  claim/1163863a-3ff8-4261-9807-6b1cef58b8eb  Claim in safety — inconclusive  working
├─ informed_by  claim/55fce2e5-b721-4dd5-87a9-3ac48960cf8b  Claim in safety — inconclusive  working
├─ informed_by  claim/3126b54e-1608-4331-9a27-dd6977e87949  Claim in safety — inconclusive  working
├─ informed_by  claim/7cf65bab-f523-407c-9374-a82b7f099e15  Claim in safety — inconclusive  working
├─ informed_by  claim/f8e8b02f-f5f6-4edb-a251-bc33472c8b11  Claim in safety — inconclusive  working
├─ informed_by  claim/1dd37364-5670-4d43-867c-e6584d3d757a  Claim in safety — inconclusive  working
├─ informed_by  claim/dd6dd083-333d-4180-920c-d2c11f4580bd  Claim in safety — inconclusive  working
├─ informed_by  claim/d3d9401f-a0e0-4e13-9d77-227b3c9d81a1  Claim in safety — inconclusive  working
├─ informed_by  claim/89d97c2b-1110-48cc-a497-fab8aed60a07  Claim in safety — inconclusive  working
├─ informed_by  claim/aeaf9a53-78db-455f-8524-4db64eb4e7da  Claim in safety — inconclusive  working
├─ informed_by  claim/e9f6db5b-73a1-44eb-97cd-455aa5cb1f6b  Claim in safety — inconclusive  working
├─ informed_by  claim/e93cf579-9d80-4351-bf39-79af14fedb3a  Claim in safety — inconclusive  working
├─ informed_by  claim/77005025-1b41-4a0e-9662-84c986f2e198  Claim in safety — inconclusive  working
├─ informed_by  claim/6fe7672b-c83e-4f4a-9373-683794f8b91c  Claim in safety — inconclusive  working
├─ informed_by  claim/12559270-63a7-4531-aa29-639c48a867b4  Claim in safety — inconclusive  working
├─ informed_by  claim/5ed6ff81-bc43-4781-bbb4-7f78ff91b42f  Claim in safety — inconclusive  working
├─ informed_by  claim/598dfe00-382b-4735-a8d8-f937369a73d0  Claim in safety — inconclusive  working
├─ informed_by  claim/65539606-eaab-47fa-813f-29fd5ff94dff  Claim in safety — inconclusive  working
├─ informed_by  claim/340ff7f0-c427-4bbe-b38e-14fbf4ccbc45  Claim in safety — inconclusive  working
├─ informed_by  claim/c845513b-eac3-455d-a58f-bbd3272b2615  Claim in safety — inconclusive  working
├─ informed_by  claim/951d5829-60e9-45c7-9a5d-c8df2f07cc56  Claim in safety — inconclusive  working
├─ informed_by  claim/5afaba1b-f28d-4334-8e6d-ef4ce53c76b6  Claim in safety — inconclusive  working
├─ informed_by  claim/92da4723-9d3f-4507-807d-93a850523563  Claim in safety — inconclusive  working
├─ informed_by  claim/10db4f42-46fc-4484-9cae-9a9a2e3b422b  Claim in safety — inconclusive  working
├─ informed_by  claim/f53fcf15-16ec-4bb8-9f7b-d563f202b3be  Claim in safety — inconclusive  working
├─ informed_by  claim/6796458a-604c-4a64-9cbc-d3713f072e79  Claim in safety — inconclusive  working
├─ informed_by  claim/10fc240b-8e2d-4eea-8cbc-e0008dc64bca  Claim in safety — inconclusive  working
├─ informed_by  claim/29bbee93-5083-4291-940d-840696d0a30c  Claim in safety — inconclusive  working
├─ informed_by  claim/df480ac3-db60-4411-af0d-621b01031e6d  Claim in safety — inconclusive  working
├─ informed_by  claim/1a4ffdb1-223d-42e8-a17d-b3b90918a8f1  Claim in safety — inconclusive  working
├─ informed_by  claim/9d717ad6-55e5-443c-b873-d0a86818433e  Claim in safety — inconclusive  working
├─ informed_by  claim/5102de9b-fae5-41f6-8d42-f5665a818325  Claim in safety — inconclusive  working
├─ informed_by  claim/51047a17-3636-49d0-95fb-c10728098c84  Claim in safety — inconclusive  working
├─ informed_by  claim/958126fd-3119-4165-9345-9062954a766b  Claim in safety — inconclusive  working
├─ informed_by  claim/6f46a55f-1de3-4ff3-9e20-b7126c4af61a  Claim in safety — inconclusive  working
├─ informed_by  claim/cc057a98-cc40-426d-8f70-8f96e1b1812e  Claim in safety — inconclusive  working
├─ informed_by  claim/4418bb06-2564-4aef-95bf-0bf23d3c7d23  Claim in safety — inconclusive  working
├─ informed_by  claim/302f6816-973f-4da9-b0be-dcf724751068  Claim in safety — inconclusive  working
├─ informed_by  claim/62b21e44-bdfc-42a5-9f77-4795651f3a3d  Claim in safety — inconclusive  working
├─ informed_by  claim/17c280d6-751f-40df-b33e-202d24a76a20  Claim in safety — inconclusive  working
├─ informed_by  claim/71c46167-6836-4d3c-a58b-829a4522be20  Claim in safety — inconclusive  working
├─ informed_by  claim/31696fe6-2120-4839-abb9-b70a092a0bff  Claim in safety — inconclusive  working
├─ informed_by  claim/fb8bc3de-2520-4a1b-bd2c-1feee96e9151  Claim in safety — inconclusive  working
├─ informed_by  claim/9ce71390-916c-4a97-991f-10c61907ca56  Claim in safety — inconclusive  working
├─ informed_by  claim/ece80563-5b65-494d-b4e1-259a8ae5b93d  Claim in safety — inconclusive  working
├─ informed_by  claim/8468ed8b-bcd1-41e6-98fb-0e2d286dd0df  Claim in safety — inconclusive  working
├─ informed_by  claim/67726c3e-d9d6-4190-8b07-990dfecb9f5f  Claim in safety — supported
├─ informed_by  claim/15bbcd5f-1c05-4f3a-8e90-18cb76bf54c8  Claim in safety — partially_supported
├─ informed_by  claim/fbbb5396-8627-472b-a97c-7d115df7bec0  Claim in safety — inconclusive  working
├─ informed_by  claim/54a06202-21d0-48fd-b743-61b05c649ca7  Claim in safety — inconclusive  working
├─ informed_by  claim/1bdb428b-610c-4fd8-9cc4-2d3f336a42b2  Claim in safety — inconclusive  working
├─ informed_by  claim/c6d16185-7cd6-4588-b477-4a2684f3b967  Claim in safety — inconclusive  working
├─ informed_by  claim/dc73ddec-b597-45e4-9820-5c2b9c49c410  Claim in safety — inconclusive  working
├─ informed_by  claim/ae7a8dc5-0fc9-47be-b361-70ed5af3fee9  Claim in safety — inconclusive  working
├─ informed_by  claim/1cb0a11a-11fa-4ed5-8d1c-6037bc1f9cc1  Claim in safety — inconclusive  working
├─ informed_by  claim/ca3a6c24-e6e0-43e3-a4ed-11f2a31cfee7  Claim in safety — inconclusive  working
  ├─ used  src/doi:10.1016/j.acvd.2014.10.003  Smokeless tobacco, sport and the heart.
  ├─ used  src/doi:10.1007/s00204-013-1127-0  How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century.
  ├─ used  src/doi:10.18433/jpps33141  A Review of Electronic Cigarettes and Liquid Nicotine Poisoning Exposure Cases in the United States.
  ├─ used  src/doi:10.4103/ijoem.ijoem_106_25  Global Burden of Green Tobacco Sickness in Farm Workers: A Systematic Review and Meta-Analysis.
  ├─ used  src/doi:10.1080/17512433.2019.1570844  Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.
  ├─ used  src/doi:10.1038/s43856-024-00584-x  Recent and projected changes in global climate may increase nicotine absorption and the risk of green tobacco sickness.
  ├─ used  src/pmid:9110108  Nicotine and sympathetic neurotransmission.
  ├─ used  src/doi:10.1111/add.15703  Tobacco use disorder and cardiovascular health.
  ├─ used  src/doi:10.1016/j.chest.2023.03.047  Cardiovascular and Pulmonary Responses to Acute Use of Electronic Nicotine Delivery Systems and Combustible Cigarettes in Long-Term Users.
  ├─ used  src/doi:10.1007/978-3-031-32554-0_10  Impact of Prenatal Nicotine Exposure on Placental Function and Respiratory Neural Network Development.
  ├─ used  src/doi:10.1016/j.amepre.2015.01.015  Nicotine and the Developing Human: A Neglected Element in the Electronic Cigarette Debate.
  ├─ used  src/pmid:23631239  Psychiatric and psychological features of nicotine dependence.
  ├─ used  src/doi:10.1016/j.neuropharm.2020.108256  Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction.
  ├─ used  src/pmid:14560040  Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography.
  ├─ used  src/pmid:9584223  Agonist-induced up-regulation of alpha4beta2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition.
  ├─ used  src/doi:10.1523/jneurosci.0546-06.2006  Human Tobacco Smokers in Early Abstinence Have Higher Levels of beta2* Nicotinic Acetylcholine Receptors than Nonsmokers.
  ├─ used  src/doi:10.1016/j.conb.2023.102797  Nicotine addiction: More than just dopamine.
  ├─ used  src/doi:10.1016/j.neubiorev.2023.105038  Age-dependent effects of tobacco smoke and nicotine on cognition and the brain: A systematic review of the human and animal literature comparing adolescents and adults.
  ├─ used  src/doi:10.1016/j.neuro.2022.09.008  A review of monoamine oxidase (MAO) inhibitors in tobacco or tobacco smoke.
  ├─ used  src/doi:10.1021/acschemneuro.4c00789  Monoamine Oxidase Inhibitors Present in Tobacco Modulate Dopamine Balance Via the Dopamine Transporter.
  ├─ used  src/doi:10.1007/s40263-025-01256-7  Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
  ├─ used  src/doi:10.1007/s00429-018-1690-5  Differential associations of combined vs. isolated cannabis and nicotine on brain resting state networks.
  ├─ used  src/doi:10.1016/j.pbb.2019.172739  Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans.
  ├─ used  src/doi:10.1007/978-3-540-69248-5_2  Nicotine chemistry, metabolism, kinetics and biomarkers.
      ├─ used  src/pmid:15734728  Metabolism and disposition kinetics of nicotine.
      ├─ used  src/url:0fb287fd7f7fa51a  Nicotine isolation history: Posselt and Reimann 1828
      ├─ used  src/doi:10.1126/sciadv.aay9763  Current advances in research in treatment and recovery: Nicotine addiction.
      ├─ used  src/doi:10.1074/jbc.M110.171645
      ├─ used  src/doi:10.1523/jneurosci.5095-09.2010  Nicotinic Acetylcholine Receptors in the Mesolimbic Pathway: Primary Role of Ventral Tegmental Area alpha6beta2* Receptors.
      ├─ used  src/doi:10.2174/1570159X15666171103152136
      ├─ used  src/doi:10.1007/s11739-019-02025-3  A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic profiles of cigarettes and e-cigarettes with nicotine salt formulations in US adult smokers.
      ├─ used  src/url:4d14e05b62716b90  FDA Tobacco Product Standard for Nicotine Yield: Proposed Rule 2025
      ├─ used  src/doi:10.57187/s.4346  Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances.
      ├─ used  src/url:029aa0370391edd8  Nicotine physical properties: CAS 54-11-5, melting point, boiling point, solubility
      ├─ used  src/pmid:15016836  The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells.
      ├─ used  src/doi:10.3390/pharmaceutics15010031  Physiologic Functions and Therapeutic Applications of alpha7 Nicotinic Acetylcholine Receptor in Brain Disorders.
      ├─ used  src/doi:10.1007/978-3-540-69248-5_8  The neuronal pathways mediating the behavioral and addictive properties of nicotine.
      ├─ used  src/doi:10.1523/JNEUROSCI.2816-18.2019
      ├─ used  src/pmid:17206524  Population pharmacokinetics of nicotine and its metabolites I. Model development.
      ├─ used  src/pmid:17112802  CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
      ├─ used  src/doi:10.1016/j.drugalcdep.2019.04.039  Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers.
      ├─ used  src/doi:10.1002/14651858.cd000146.pub4  Nicotine replacement therapy for smoking cessation
      ├─ used  src/doi:10.1002/14651858.CD013308.pub2
      ├─ derived_from  gen/ef6640ce-d920-41f7-9ffa-d4cbc4104826  Generation — pipeline-v5
      └─ generated_by  pub/5ed3ce14-df05-46ad-8a40-2864d5f94da1  Publication — backfill
    ├─ used  version/1  Revision 1
    ├─ used  claim/e74282e0-2f93-4c33-9b33-94371c44f775  Claim in summary — inconclusive  working
    ├─ used  claim/9dac4194-57aa-4c31-b16e-e6325e1451de  Claim in summary — inconclusive  working
    ├─ used  claim/ca3ad269-3e22-4dd9-a1f9-b2f652b18551  Claim in pharmacology — inconclusive  working
    ├─ used  claim/fba3fc58-f5d7-4f36-bacc-228651b8acdf  Claim in neuroscience — inconclusive  working
    ├─ used  claim/ac3663a8-c9de-4853-b878-d2d74e3b982f  Claim in pharmacology — inconclusive  working
    ├─ used  claim/12fe05d1-7534-4410-b394-961490abfc78  Claim in neuroscience — inconclusive  working
    ├─ used  claim/10dac44f-33c2-4787-83b6-e3a484f407cc  Claim in neuroscience — inconclusive  working
    ├─ used  claim/b2437d90-b9a0-424d-b5a2-33a4c73d4957  Claim in neuroscience — inconclusive  working
    ├─ used  claim/eadcbac4-76de-49bb-8cea-1e64a4ea6e02  Claim in summary — inconclusive  working
    ├─ used  claim/0bd47cf6-bfaf-4056-b646-f675b18727d1  Claim in summary — inconclusive  working
    ├─ used  claim/856b1298-1731-4f6b-8904-7f5e2cfe061a  Claim in pharmacology — inconclusive  working
    ├─ used  claim/b1ccef51-c310-4072-8f5f-b31bc2d7f14e  Claim in pharmacology — inconclusive  working
    ├─ used  claim/c1801a73-00c9-48e2-85ff-c10afef0e43b  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/ab3bb2d5-7584-4dbe-896e-261e92487e56  Claim in neuroscience — inconclusive  working
    ├─ used  claim/01be5449-f6a2-42cb-984d-f7cdcb61a4f4  Claim in neuroscience — inconclusive  working
    ├─ used  claim/05cdd886-974a-4124-85c5-44f82024b17f  Claim in pharmacology — inconclusive  working
    ├─ used  claim/4cdc86eb-9f0d-4f9a-a7c0-c5b84d25a4c7  Claim in pharmacology — inconclusive  working
    ├─ used  claim/1a08d783-ec1b-4889-b194-d448167249cf  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/c60a2ba6-afd2-4685-8820-1674e84f7451  Claim in neuroscience — inconclusive  working
    ├─ used  claim/f332c44e-c509-4824-b7cb-b0fed447f9d1  Claim in neuroscience — inconclusive  working
    ├─ used  claim/e4286e09-98af-42bf-ba08-bac5f5616a8d  Claim in summary — inconclusive  working
    ├─ used  claim/f35ede74-607c-4f5e-99b9-1c879ec6557a  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/aadf6db1-8f97-49fa-b5aa-4767e3d3f2d4  Claim in neuroscience — inconclusive  working
    ├─ used  claim/75ef3add-3a6f-45f3-901c-76f4f7e3ef4a  Claim in summary — inconclusive  working
    ├─ used  claim/d7135203-9d4d-4be2-9bf4-e9ae16d9ceca  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/19457dfe-b789-46fa-b276-f7b4e2fc54dc  Claim in neuroscience — inconclusive  working
    ├─ used  claim/b3af7d83-1aa4-4d2e-a456-25d64e439bde  Claim in neuroscience — inconclusive  working
    ├─ used  claim/d4646cb3-e960-45ba-8f51-8f378bcb9ad9  Claim in neuroscience — inconclusive  working
    ├─ used  claim/ddf58528-fda5-4a2d-99d8-279086fe9055  Claim in neuroscience — inconclusive  working
    ├─ used  claim/a8dcf147-8f32-484f-965d-8ae8873c47f0  Claim in neuroscience — inconclusive  working
    ├─ used  claim/f32a444c-ab54-46e3-94e4-bf0da510a00b  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/36d46714-e1ea-4943-a36d-35b5b985e5c9  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/9f0c5b0e-8016-4299-9e80-76cdcf530cdc  Claim in neuroscience — inconclusive  working
    ├─ used  claim/b5a70a8a-1e6d-42a9-aebf-3cc770777979  Claim in pharmacology — inconclusive  working
    ├─ used  claim/a76b771f-c791-4744-98c1-ae6c0684f515  Claim in pharmacology — inconclusive  working
    ├─ used  claim/3acf3381-ee58-4f29-aba4-427dfa53c983  Claim in pharmacology — inconclusive  working
    ├─ used  claim/e457c708-4c21-4ef4-946a-b847f2ee5871  Claim in effects-overview — inconclusive  working
    ├─ used  claim/c7d935b7-cf29-4976-8a43-095a743d3869  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/fd1b8c60-673c-4e1e-b71f-5938c2aa963e  Claim in neuroscience — inconclusive  working
    ├─ used  claim/ccbb2369-432c-44bb-ba65-66367f3f323a  Claim in pharmacology — inconclusive  working
    ├─ used  claim/b8dd2939-5e37-4aea-bf85-1c81f3e840d3  Claim in pharmacology — inconclusive  working
    ├─ used  claim/bab72b5b-4e09-4127-9644-16923a6d220e  Claim in pharmacology — inconclusive  working
    ├─ used  claim/32f8c18f-7c1c-4721-9436-a9c72caa2c45  Claim in neuroscience — inconclusive  working
    ├─ used  claim/f9db6702-dbab-4376-9fce-109df5bbc67f  Claim in effects-overview — inconclusive  working
    ├─ used  claim/631ed30b-b34c-43d4-9d27-3938f8bbadd7  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/639bc9f9-f477-4bc4-b8c1-3218e07dcf73  Claim in neuroscience — inconclusive  working
    ├─ used  claim/2579891c-7e91-4659-8cd7-5c936fbad260  Claim in neuroscience — inconclusive  working
    ├─ used  claim/63fd514a-25db-4f55-91b4-2ab61ef11b9b  Claim in neuroscience — inconclusive  working
    ├─ used  claim/431177a8-85e2-4cfa-bf68-1e1134e9d80c  Claim in neuroscience — inconclusive  working
    ├─ used  claim/946e84d1-23f6-45df-bbe7-a86eb361fd0b  Claim in neuroscience — inconclusive  working
    ├─ used  claim/31ef9d3b-b68a-4d6a-886a-c3016f4d525d  Claim in pharmacology — inconclusive  working
    ├─ used  claim/933a435d-50df-4c83-82db-c55c3293fb52  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/59bf2032-92ad-4831-aa9d-e31070716a6e  Claim in pharmacology — inconclusive  working
    ├─ used  claim/f231a580-997d-458c-8995-b04761c50227  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/59b1d30e-8d22-469c-b69c-134605b28b51  Claim in pharmacology — inconclusive  working
    ├─ used  claim/e16f87d1-ec38-4bef-825d-9c0dd464c27d  Claim in pharmacology — supported
    ├─ used  claim/40a6e5af-f892-4f50-b22c-e18d989c6f95  Claim in neuroscience — inconclusive  working
    ├─ used  claim/4e6cce53-77da-43bb-904f-0598089f5bc6  Claim in neuroscience — inconclusive  working
    ├─ used  claim/0e5f9abd-c0d4-4cfc-83eb-4fa33f1ef9dd  Claim in pharmacology — inconclusive  working
    ├─ used  claim/d0e35521-22ce-4b55-9f27-b6bada506e14  Claim in pharmacology — inconclusive  working
    ├─ used  claim/c6115260-d9c8-4b91-b433-f141e6f19cd8  Claim in pharmacology — inconclusive  working
    ├─ used  claim/01a0aaa9-6a6f-4349-8944-4229f09e79a8  Claim in chemistry — inconclusive  working
    ├─ used  claim/b1f8ce77-9097-4e3f-817f-0f46a018e6d8  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/5f74870c-4bf0-4bf6-9f56-d66f75019d31  Claim in pharmacology — inconclusive  working
    ├─ used  claim/9d37f53b-94c0-481f-bcee-1ca0081c067d  Claim in pharmacology — inconclusive  working
    ├─ used  claim/0b6d0b03-0738-4c81-ba45-031317e3ce61  Claim in pharmacology — inconclusive  working
    ├─ used  claim/578ea5c1-01b0-40a1-8bba-6b3085fa273b  Claim in chemistry — inconclusive  working
    ├─ used  claim/a2ebde23-6c98-4399-bf65-02ac04e7bf19  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ derived_from  issue/notice@f8bfb1cb8b0a  Issued notice
      ├─ derived_from  issue/info_card@1eec9c7c323c  Issued info_card
      ├─ derived_from  issue/emergency@777b5863d801  Issued emergency
      ├─ derived_from  issue/info_card@0620683a29b0  Issued info_card
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/pharmacology.full@1
      ├─ informed_by  section/neuroscience.full@1
      ├─ informed_by  section/comparative-pharmacology.full@1
      ├─ informed_by  section/receptor-pharmacology.full@1
      ├─ informed_by  section/effects-overview.full@1
      ├─ informed_by  section/chemistry.full@1
      └─ informed_by  section/pharmacokinetic-detail.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

4332 with DOI

7 strong · 33 moderate · 3 weak

Compilations

22026-04-25T19:20:50.898Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

60last ruled 2026-06-04

1 awaiting a ruling

Issued documents

42026-10-19T20:33:19.402Z

notice · info card · emergency

Searches

190 with no results

queries and counts on the build

Claims checked

1983 supported

3 supported · 195 not

Correspondence

0received

consent field ships in Phase 4

Edges

530

derivations recorded for this entity

Complete over 43 sources, 2 compilations, and 60 decisions.Not here: the private journal (never); 1 proposal awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/nicotine/archive

2Build

one panel per compilation run

generation run 2026-04-25

5 min failedmodel not recordedplan not recordedrun/0ba2510e…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources43

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
43 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-04-25

60 min completedmodel pipeline-v5plan not recordedrun/90415aee…

research

citationsRegistryrecordresearchOutputworking

draft

articleDraftworking

audit

articleAuditedworking

verify

verificationResultworking

simplify

articleSimplifiedworking

publish

runMetarecordrunSummaryrecord

Selection

results seen127
selected by the model35
consumed as sources43

Verification

claims checked198
supported2
partially supported1
not supported0
inconclusive195
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
43 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
19 searches — query, source, results, what was kept and why
19 searches for this run
#sourcequeryseenkeptrationale
1PubChemnicotine11Primary chemical identity verification for nicotine
2PubMednicotine pharmacokinetics plasma half-life cotinine metabolism CYP2A6 human74Core pharmacokinetic papers on CYP2A6 metabolism of nicotine
3OpenAlexnicotine nicotinic acetylcholine receptor pharmacology80—
4PubMednicotine pharmacology receptor binding mechanism action120—
5PubMednicotine addiction dependence withdrawal dopamine reward mesolimbic103Key reviews on addiction neuroscience and dopamine/non-dopamine mechanisms
6PubMednicotine pharmacokinetics bioavailability metabolism CYP human20—
7PubMedgreen tobacco sickness nicotine poisoning workers83Nicotine toxicity data via dermal absorption
8PubMedBenowitz nicotine clinical pharmacology review human103Comprehensive Benowitz-authored reviews covering nicotine pharmacology, toxicology, and addiction
9ClinicalTrials.govnicotine pharmacology addiction treatment103Relevant completed trials on nicotine dependence pharmacotherapy
10PubMedHukkanen nicotine metabolism pharmacokinetics review pharmacological22Landmark comprehensive pharmacokinetics reviews
11WebSearchnicotine isolation history 1828 Posselt Reimann discovery tobacco alkaloid102—
12WebSearchnicotine SMILES CAS 54-11-5 physical properties melting point boiling point101—
13PubChem via WebFetchNicotine CID 8959410—
14WebSearchMayer 2014 nicotine lethal dose LD50 re-evaluation Archives of Toxicology101—
15DOI Verification10.1007/s00204-013-1127-011—
16PubMedPMID 40811135, 31663029, 15734728, 19184645, 32738308, 3783239366—
17ClinicalTrials.govnicotine Parkinson disease cognitive neuroprotection11—
18PubMedtobacco smoke monoamine oxidase inhibition MAOI nicotine beta-carboline83—
19WebSearchnicotine legal status scheduling United States FDA regulated tobacco product101—
198 claims by section — every cited sentence, checked against its source
safety62 · 2 ok

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Tobacco smoke contains multiple monoamine-oxidase inhibitors — β-carbolines (harman, norharman, harmaline), hydroquinones, and polyunsaturated fatty acids — that potentiate dopaminergic effects of nicotine by reducing dopamine degradation and stimulating dopamine-transporter-mediated dopamine releasesupported

    Harmaline inhibits MAO-A and significantly attenuates DAT activity and dopamine uptake; also promotes dopamine release in synaptosomes. acschemneuro.4c00789

  • A review of 219 publications found that nicotine can be used with careful monitoring in patients taking pharmaceutical MAOIs; the interaction does not carry serotonin-syndrome risk but requires monitoring for cardiovascular effects (blood pressure and heart rate augmentation)partially supported

    Narrative review investigating MAOI use in patients who use psychoactive substances. Suspected cases of serotonin toxicity reported for MAOIs in combination with DXM. Hypertensive urgency/emergency reported for MAOIs with multiple substances. s40263-025-01256-7

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

pharmacology48 · 1 ok

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • An important pharmacological distinction: β-carboline monoamine-oxidase inhibitors (harman, norharman, harmaline) present in tobacco smoke potentiate dopaminergic effects by reducing dopamine degradation and stimulating dopamine-transporter-mediated dopamine releasesupported

    Harmaline inhibits MAO-A and significantly attenuates DAT activity and dopamine uptake; also promotes dopamine release in synaptosomes. acschemneuro.4c00789

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

neuroscience28 · 0 ok

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

summary18 · 0 ok

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

pharmacokinetic-detail12 · 0 ok

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

receptor-pharmacology10 · 0 ok

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

comparative-pharmacology8 · 0 ok

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

clinical-evidence4 · 0 ok

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

effects-overview4 · 0 ok

  • Claim in effects-overview — inconclusiveinconclusiveworking →

  • Claim in effects-overview — inconclusiveinconclusiveworking →

  • Claim in effects-overview — inconclusiveinconclusiveworking →

  • Claim in effects-overview — inconclusiveinconclusiveworking →

chemistry2 · 0 ok

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Claim in chemistry — inconclusiveinconclusiveworking →

history2 · 0 ok

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

3Sources

43 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
yearsourcetierstatusfeeds
2026Global Burden of Green Tobacco Sickness in Farm Workers: A Systematic Review and Meta-Analysis.Jahromi HK et al. · Indian journal of occupational and environmental medicinedoi:10.4103/ijoem.ijoem_106_25strongconsumed1 section
2026Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive SubstancesRached G, Campana A, Fiani D, et al. · CNS Drugsdoi:10.1007/s40263-025-01256-7strongconsumed1 section
2025Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances.Christen SE, Bekka E, Schmid Y, Benowitz NL, Liakoni E · Swiss medical weeklydoi:10.57187/s.4346moderateconsumedcited only
2025FDA Tobacco Product Standard for Nicotine Yield: Proposed Rule 2025US FDAurl:4d14e05b62716b90weakconsumedcited only
2025Monoamine Oxidase Inhibitors Present in Tobacco Modulate Dopamine Balance Via the Dopamine Transporter.Saro G, Johne S, Latino DARS et al. · ACS chemical neurosciencedoi:10.1021/acschemneuro.4c00789moderateconsumed2 sections
2024Nicotine physical properties: CAS 54-11-5, melting point, boiling point, solubilityVarious chemical databasesurl:029aa0370391edd8weakconsumedcited only
2024Recent and projected changes in global climate may increase nicotine absorption and the risk of green tobacco sickness.Ziska LH, Parks RM · Communications medicinedoi:10.1038/s43856-024-00584-xmoderateconsumed1 section
2023Age-dependent effects of tobacco smoke and nicotine on cognition and the brain: A systematic review of the human and animal literature comparing adolescents and adults.Colyer-Patel K, Kuhns L, Weidema A, Lesscher H, Cousijn J · Neuroscience and biobehavioral reviewsdoi:10.1016/j.neubiorev.2023.105038strongconsumed2 sections
2023Cardiovascular and Pulmonary Responses to Acute Use of Electronic Nicotine Delivery Systems and Combustible Cigarettes in Long-Term Users.Tattersall MC, Hughey CM, Piasecki TM et al. · Chestdoi:10.1016/j.chest.2023.03.047moderateconsumed1 section
2023Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.Theodoulou A, Chepkin SC, Ye W et al. · The Cochrane database of systematic reviewsdoi:10.1002/14651858.cd013308.pub2strongconsumedcited only
2023Impact of Prenatal Nicotine Exposure on Placental Function and Respiratory Neural Network Development.Beltran-Castillo S, Bravo K, Eugeniu J · Advances in experimental medicine and biologydoi:10.1007/978-3-031-32554-0_10moderateconsumed2 sections
2023Nicotine addiction: More than just dopamine.Kim K, Picciotto MR · Current opinion in neurobiologydoi:10.1016/j.conb.2023.102797moderateconsumed5 sections
2022A Review of Electronic Cigarettes and Liquid Nicotine Poisoning Exposure Cases in the United States.Ahmed A · Journal of pharmacy & pharmaceutical sciencesdoi:10.18433/jpps33141moderateconsumed1 section
2022A review of monoamine oxidase (MAO) inhibitors in tobacco or tobacco smoke.Hong SW, Teesdale-Spittle P, Page R, Truman P · Neurotoxicologydoi:10.1016/j.neuro.2022.09.008moderateconsumed3 sections
2022Physiologic Functions and Therapeutic Applications of alpha7 Nicotinic Acetylcholine Receptor in Brain Disorders.Lee CH, Hung SY · Pharmaceuticsdoi:10.3390/pharmaceutics15010031moderateconsumed2 sections
2022Tobacco use disorder and cardiovascular health.Benowitz NL, Liakoni E · Addiction (Abingdon, England)doi:10.1111/add.15703moderateconsumed1 section
2020Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction.Wittenberg RE, Wolfman SL, De Biasi M, Dani JA · Neuropharmacologydoi:10.1016/j.neuropharm.2020.108256moderateconsumed4 sections
2019A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic profiles of cigarettes and e-cigarettes with nicotine salt formulations in US adult smokers.O'Connell G, Pritchard JD, Prue C et al. · Internal and emergency medicinedoi:10.1007/s11739-019-02025-3strongconsumed1 section
2019Acute separate and combined effects of cannabinoid and nicotinic receptor agonists on MMN-indexed auditory deviance detection in healthy humans.de la Salle S, Inyang L, Impey D et al. · Pharmacology, biochemistry, and behaviordoi:10.1016/j.pbb.2019.172739strongconsumed2 sections
2019Chronic Nicotine Exposure Alters the Neurophysiology of Habenulo-Interpeduncular Circuitry.Arvin MC, Jin XT, Yan Y et al. · The Journal of neurosciencedoi:10.1523/jneurosci.2816-18.2019moderateconsumedcited only
2019Current advances in research in treatment and recovery: Nicotine addiction.Prochaska JJ, Benowitz NL · Science advancesdoi:10.1126/sciadv.aay9763moderateconsumed1 section
2019Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.McMahon LR · Expert review of clinical pharmacologydoi:10.1080/17512433.2019.1570844moderateconsumed1 section
2019Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers.Liakoni E, St Helen G, Dempsey DA, Jacob P, Tyndale RF, Benowitz NL · Drug and alcohol dependencedoi:10.1016/j.drugalcdep.2019.04.039moderateconsumed1 section
2018Cognitive Effects of Nicotine: Recent Progress.Valentine G, Sofuoglu M · Current neuropharmacologydoi:10.2174/1570159x15666171103152136moderateconsumedcited only
2018Differential associations of combined vs. isolated cannabis and nicotine on brain resting state networks.Filbey FM, Gohel S, Prashad S, Biswal BB · Brain structure & functiondoi:10.1007/s00429-018-1690-5moderateconsumed1 section
2015Nicotine and the Developing Human: A Neglected Element in the Electronic Cigarette Debate.England LJ, Bunnell RE, Pechacek TF, Tong VT, McAfee TA · American journal of preventive medicinedoi:10.1016/j.amepre.2015.01.015moderateconsumed1 section
2015Smokeless tobacco, sport and the heart.Chague F, Guenancia C, Gudjoncik A et al. · Archives of cardiovascular diseasesdoi:10.1016/j.acvd.2014.10.003moderateconsumed1 section
2014How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century.Mayer B · Archives of toxicologydoi:10.1007/s00204-013-1127-0moderateconsumed2 sections
2013Psychiatric and psychological features of nicotine dependence.Miyasato K · Nihon rinsho. Japanese journal of clinical medicinepmid:23631239moderateconsumed2 sections
2012Nicotine replacement therapy for smoking cessationStead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J · Cochrane Database of Systematic Reviewsdoi:10.1002/14651858.cd000146.pub4strongconsumed1 section
Show all 43 sources — 13 more
Sources 31 to 43
yearsourcetierstatusfeeds
2011Expression of water-soluble, ligand-binding concatameric extracellular domains of the human neuronal nicotinic receptor alpha4 and beta2 subunits.Stergiou C, Zisimopoulou P, Tzartos SJ · The Journal of biological chemistrydoi:10.1074/jbc.m110.171645moderateconsumedcited only
2010Nicotinic Acetylcholine Receptors in the Mesolimbic Pathway: Primary Role of Ventral Tegmental Area alpha6beta2* Receptors.Gotti C, Guiducci S, Tedesco V et al. · Journal of Neurosciencedoi:10.1523/jneurosci.5095-09.2010moderateconsumed4 sections
2009Nicotine chemistry, metabolism, kinetics and biomarkers.Benowitz NL, Hukkanen J, Jacob P · Handbook of experimental pharmacologydoi:10.1007/978-3-540-69248-5_2moderateconsumed4 sections
2009The neuronal pathways mediating the behavioral and addictive properties of nicotine.Balfour DJ · Handbook of experimental pharmacologydoi:10.1007/978-3-540-69248-5_8moderateconsumed2 sections
2007Population pharmacokinetics of nicotine and its metabolites I. Model development.Levi M, Dempsey DA, Benowitz NL, Sheiner LB · Journal of pharmacokinetics and pharmacodynamicspmid:17206524moderateconsumed2 sections
2006CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.Benowitz NL, Swan GE, Jacob P, Lessov-Schlaggar CN, Tyndale RF · Clinical pharmacology and therapeuticspmid:17112802moderateconsumed2 sections
2006Human Tobacco Smokers in Early Abstinence Have Higher Levels of beta2* Nicotinic Acetylcholine Receptors than Nonsmokers.Staley JK, Krishnan-Sarin S, Cosgrove K et al. · Journal of Neurosciencedoi:10.1523/jneurosci.0546-06.2006moderateconsumed2 sections
2005Metabolism and disposition kinetics of nicotine.Hukkanen J, Jacob P, Benowitz NL · Pharmacological reviewspmid:15734728moderateconsumed4 sections
2004The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells.Xiao Y, Kellar KJ · The Journal of pharmacology and experimental therapeuticspmid:15016836moderateconsumed2 sections
2003Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography.Nguyen HN, Rasmussen BA, Perry DC · The Journal of pharmacology and experimental therapeuticspmid:14560040moderateconsumed4 sections
1998Agonist-induced up-regulation of alpha4beta2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition.Whiteaker P, Sharples CG, Wonnacott S · Molecular pharmacologypmid:9584223moderateconsumed2 sections
1997Nicotine and sympathetic neurotransmission.Haass M, Kubler W · Cardiovascular drugs and therapypmid:9110108moderateconsumed3 sections
1828Nicotine isolation history: Posselt and Reimann 1828Variousurl:0fb287fd7f7fa51aweakconsumedcited only

4Docket

one filing per activity — decisions, correspondence, reports

awaiting ruling — 1

  • dependence · tapercited2026-07-03
  1. 0012026-04-25revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki)

    psx:substance/nicotine/version/1
  2. 0022026-06-04proposal57 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    57 items in this filing

    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · smoked · onset
    • timeline · smoked · come_up
    • timeline · smoked · peak
    • timeline · smoked · plateau
    • timeline · smoked · resolution
    • timeline · smoked · afterglow
    • timeline · buccal · onset
    • timeline · buccal · come_up
    • timeline · buccal · peak
    • timeline · buccal · plateau
    • timeline · buccal · resolution
    • timeline · buccal · afterglow
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · plateau
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · smoked
    • dosage · buccal
    • dosage · transdermal
    • duration · smoked · onset
    • duration · smoked · come_up
    • duration · smoked · peak
    • duration · smoked · offset
    • duration · smoked · total
    • duration · smoked · aftereffects
    • duration · buccal · onset
    • duration · buccal · come_up
    • duration · buccal · peak
    • duration · buccal · offset
    • duration · buccal · total
    • duration · buccal · aftereffects
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    • contraindication · pregnancy_breastfeeding
    • contraindication · pregnancy_breastfeeding
    • contraindication · cardiovascular
    • contraindication · cardiovascular
    • contraindication · cardiovascular
    • contraindication · cardiovascular
    • contraindication · metabolic
    • contraindication · other
    • contraindication · age
    psx:substance/nicotine/proposal/dose_tier/963922ab-2697-4fb8-890d-eb9c6bc8d467
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/nicotine/pub/5ed3ce14-df05-46ad-8a40-2864d5f94da1

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
info_card0620683a29b02ddcb25c21d7…2026-10-19 20:33Revision 1current
emergency777b5863d801327b008f5610…2026-09-04 04:31Revision 1current
info_card1eec9c7c323c4e1aceb7f4fd…2026-09-04 04:31Revision 1superseded2026-10-19
noticef8bfb1cb8b0a2f3da7fc6a2c…2026-09-04 04:31Revision 1current